Business Description
Walvax Biotechnology Co Ltd
NAICS : 325412
SIC : 2834
ISIN : CNE100000WN2
Share Class Description:
SZSE:300142: Class ACompare
Compare
Traded in other countries / regions
300142.China IPO Date
2011-03-10Description
Walvax Biotechnology Co Ltd is engaged in research and development, production and sales of vaccine products.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.45 | |||||
| Equity-to-Asset | 0.63 | |||||
| Debt-to-Equity | 0.08 | |||||
| Debt-to-EBITDA | 2.93 | |||||
| Interest Coverage | 82.61 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 5.05 | |||||
| Beneish M-Score | -2.69 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 10.9 | |||||
| 3-Year EBITDA Growth Rate | -15.7 | |||||
| 3-Year EPS without NRI Growth Rate | -7.9 | |||||
| 3-Year Book Growth Rate | 11.2 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 22.07 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 98.48 | |||||
| 9-Day RSI | 95.17 | |||||
| 14-Day RSI | 90.52 | |||||
| 6-1 Month Momentum % | -32.45 | |||||
| 12-1 Month Momentum % | -56.92 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.94 | |||||
| Quick Ratio | 2.54 | |||||
| Cash Ratio | 1.31 | |||||
| Days Inventory | 641.33 | |||||
| Days Sales Outstanding | 350.69 | |||||
| Days Payable | 1101.46 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.06 | |||||
| Dividend Payout Ratio | 0.03 | |||||
| 3-Year Dividend Growth Rate | -20.6 | |||||
| Forward Dividend Yield % | 0.06 | |||||
| 5-Year Yield-on-Cost % | 0.06 | |||||
| 3-Year Average Share Buyback Ratio | -1.3 | |||||
| Shareholder Yield % | -0.98 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 81.9 | |||||
| Operating Margin % | 18.29 | |||||
| Net Margin % | 3.99 | |||||
| FCF Margin % | 1.55 | |||||
| ROE % | 1.43 | |||||
| ROA % | 0.87 | |||||
| ROIC % | 5.41 | |||||
| ROC (Joel Greenblatt) % | 4.77 | |||||
| ROCE % | 2.06 | |||||
| Years of Profitability over Past 10-Year | 8 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 211.9 | |||||
| Forward PE Ratio | 37.08 | |||||
| PE Ratio without NRI | 54.27 | |||||
| Shiller PE Ratio | 98.89 | |||||
| PEG Ratio | 13.57 | |||||
| PS Ratio | 8.46 | |||||
| PB Ratio | 3.01 | |||||
| Price-to-Tangible-Book | 3.57 | |||||
| Price-to-Free-Cash-Flow | 556.24 | |||||
| Price-to-Operating-Cash-Flow | 33.89 | |||||
| EV-to-EBIT | 100.93 | |||||
| EV-to-EBITDA | 100.93 | |||||
| EV-to-Revenue | 7.65 | |||||
| EV-to-FCF | 399.47 | |||||
| Price-to-Projected-FCF | 5.65 | |||||
| Price-to-Median-PS-Value | 0.31 | |||||
| Price-to-Graham-Number | 2.93 | |||||
| Price-to-Net-Current-Asset-Value | 14.96 | |||||
| Earnings Yield (Greenblatt) % | 0.99 | |||||
| FCF Yield % | 0.18 | |||||
| Forward Rate of Return (Yacktman) % | -0.76 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Walvax Biotechnology Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 3,379.45 | ||
| EPS (TTM) (Â¥) | 0.084 | ||
| Beta | 1.49 | ||
| Volatility % | 61.35 | ||
| 14-Day RSI | 90.52 | ||
| 14-Day ATR (Â¥) | 0.73442 | ||
| 20-Day SMA (Â¥) | 10.8915 | ||
| 12-1 Month Momentum % | -56.92 | ||
| 52-Week Range (Â¥) | 9.78 - 25.45 | ||
| Shares Outstanding (Mil) | 1,599.35 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Walvax Biotechnology Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Walvax Biotechnology Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Walvax Biotechnology Co Ltd Frequently Asked Questions
What is Walvax Biotechnology Co Ltd(SZSE:300142)'s stock price today?
The current price of SZSE:300142 is ¥17.80. The 52 week high of SZSE:300142 is ¥25.45 and 52 week low is ¥9.78.
When is next earnings date of Walvax Biotechnology Co Ltd(SZSE:300142)?
The next earnings date of Walvax Biotechnology Co Ltd(SZSE:300142) is .
Does Walvax Biotechnology Co Ltd(SZSE:300142) pay dividends? If so, how much?
The Dividend Yield %  of Walvax Biotechnology Co Ltd(SZSE:300142) is 0.06% (As of Today), Highest Dividend Payout Ratio of Walvax Biotechnology Co Ltd(SZSE:300142) was 0.36. The lowest was 0.03. And the median was 0.07. The  Forward Dividend Yield % of Walvax Biotechnology Co Ltd(SZSE:300142) is 0.06%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers